TW202333772A - 使用介白素-2藥劑之方法 - Google Patents

使用介白素-2藥劑之方法 Download PDF

Info

Publication number
TW202333772A
TW202333772A TW111146169A TW111146169A TW202333772A TW 202333772 A TW202333772 A TW 202333772A TW 111146169 A TW111146169 A TW 111146169A TW 111146169 A TW111146169 A TW 111146169A TW 202333772 A TW202333772 A TW 202333772A
Authority
TW
Taiwan
Prior art keywords
amino acid
seq
fusion protein
variant
fold
Prior art date
Application number
TW111146169A
Other languages
English (en)
Chinese (zh)
Inventor
格高里 貝比卡克
韋恩 漢考克
Original Assignee
美商威特拉公司
美國費城兒童醫院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商威特拉公司, 美國費城兒童醫院 filed Critical 美商威特拉公司
Publication of TW202333772A publication Critical patent/TW202333772A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111146169A 2021-12-01 2022-12-01 使用介白素-2藥劑之方法 TW202333772A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163284978P 2021-12-01 2021-12-01
US63/284,978 2021-12-01
US202263348201P 2022-06-02 2022-06-02
US63/348,201 2022-06-02

Publications (1)

Publication Number Publication Date
TW202333772A true TW202333772A (zh) 2023-09-01

Family

ID=84981477

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111146169A TW202333772A (zh) 2021-12-01 2022-12-01 使用介白素-2藥劑之方法

Country Status (10)

Country Link
US (1) US20240041981A1 (https=)
EP (1) EP4440598A1 (https=)
JP (1) JP2024543209A (https=)
KR (1) KR20250169356A (https=)
CN (1) CN120131911A (https=)
AU (1) AU2022399832A1 (https=)
CA (1) CA3238574A1 (https=)
MX (1) MX2024006746A (https=)
TW (1) TW202333772A (https=)
WO (1) WO2023102463A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3147757A1 (en) 2019-07-26 2021-02-04 Visterra, Inc. Interleukin-2 agents and uses thereof
EP4255466A1 (en) 2020-12-04 2023-10-11 Visterra, Inc. Methods of using interleukin-2 agents
WO2025221954A1 (en) * 2024-04-17 2025-10-23 Visterra, Inc. Use of il-2 variant for treating kidney transplant rejection
CN119638850A (zh) * 2024-11-07 2025-03-18 浙江大学 双特异性细胞因子融合蛋白及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8905669D0 (en) 1989-03-13 1989-04-26 Celltech Ltd Modified antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE352612T1 (de) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
IT1395574B1 (it) 2009-09-14 2012-10-16 Guala Dispensing Spa Dispositivo di erogazione
US9580486B2 (en) * 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
PH12017501856B1 (en) * 2015-04-10 2022-08-10 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
KR102687530B1 (ko) 2016-05-04 2024-07-25 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
SG11201900616UA (en) 2016-08-02 2019-02-27 Visterra Inc Engineered polypeptides and uses thereof
US20210017247A1 (en) * 2017-07-03 2021-01-21 Torque Therapeutics, Inc. Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof
CA3147757A1 (en) 2019-07-26 2021-02-04 Visterra, Inc. Interleukin-2 agents and uses thereof

Also Published As

Publication number Publication date
KR20250169356A (ko) 2025-12-03
CA3238574A1 (en) 2023-06-08
JP2024543209A (ja) 2024-11-19
CN120131911A (zh) 2025-06-13
WO2023102463A1 (en) 2023-06-08
US20240041981A1 (en) 2024-02-08
EP4440598A1 (en) 2024-10-09
AU2022399832A1 (en) 2024-06-06
MX2024006746A (es) 2024-08-09

Similar Documents

Publication Publication Date Title
JP7516254B2 (ja) Il-15/il-15raヘテロ二量体fc融合タンパク質およびその使用
JP6840908B1 (ja) エフェクター機能が除去されたIgG1 Fc変異体
US12084484B2 (en) Interleukin-2 agents and uses thereof
TW202333772A (zh) 使用介白素-2藥劑之方法
US20250002601A1 (en) Multispecific antibodies binding to cd20, nkp46, cd16 and conjugated to il-2
US20110158995A1 (en) Multi-Specific Binding Proteins Targeting B Cell Disorders
CN110214147A (zh) IL15/IL15Rα异源二聚体FC-融合蛋白
JP2021502826A (ja) Dドメイン含有ポリペプチドおよびその使用
KR20230127306A (ko) NKp46 및 CD123에 결합하는 다기능성 자연살해(NK)세포 관여자
US12098178B2 (en) Methods of using interleukin-2 agents
JP2020535819A (ja) Cd3/cd33二重特異性結合分子
TW202043281A (zh) 抗cd38結合結構域
CN120584127A (zh) 包含d结构域的多肽及其用途
CN114867751B (zh) 4-1bb和ox40结合蛋白及相关组合物和方法、抗-4-1bb抗体、抗-ox40抗体
HK40128460A (zh) 使用白细胞介素-2药剂的方法
HK40111234A (zh) 使用白细胞介素-2药剂的方法
CN118871123A (zh) 使用白细胞介素-2药剂的方法
RU2827796C2 (ru) Гетеродимерные слитые белки ИЛ-15/ИЛ-15Рα - Fc и их применение
HK40101528A (zh) 结合至cd20、nkp46、cd16并缀合至il-2的多特异性抗体
RU2779938C2 (ru) ГЕТЕРОДИМЕРНЫЕ Fc-СЛИТЫЕ БЕЛКИ IL15/IL15Rα
WO2024251884A1 (en) Nk cell engager proteins comprising anti-cd20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl
CN116731161A (zh) 工程化IgG和IgA嵌合的“四叶草型X抗体”
TW202604940A (zh) 介白素-2藥劑及其用途
HK40078517B (zh) 4-1bb和ox40结合蛋白及相关组合物和方法、抗-4-1bb抗体、抗-ox40抗体